

# Rabies - Pipeline Review, H2 2020

<https://marketpublishers.com/r/R67EB50D79DEN.html>

Date: October 2020

Pages: 108

Price: US\$ 2,000.00 (Single User License)

ID: R67EB50D79DEN

## Abstracts

Rabies - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H2 2020, provides an overview of the Rabies (Infectious Disease) pipeline landscape.

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 4, 5, 1, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I,

Preclinical and Discovery stages comprises 1, 2, 6 and 1 molecules, respectively.

Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Rabies - Overview

Rabies - Therapeutics Development

Rabies - Therapeutics Assessment

Rabies - Companies Involved in Therapeutics Development

Rabies - Drug Profiles

Rabies - Dormant Projects

Rabies - Discontinued Products

Rabies - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Rabies, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020

Rabies - Pipeline by Cadila Healthcare Ltd, H2 2020

Rabies - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2020

Rabies - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H2 2020

Rabies - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020

Rabies - Pipeline by CPL Biologicals Pvt Ltd, H2 2020

Rabies - Pipeline by Curevac AG, H2 2020

Rabies - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, H2 2020

Rabies - Pipeline by GlaxoSmithKline Plc, H2 2020

Rabies - Pipeline by Humabs BioMed SA, H2 2020

Rabies - Pipeline by Indian Immunologicals Ltd, H2 2020

Rabies - Pipeline by Mid-Atlantic BioTherapeutics, Inc., H2 2020

Rabies - Pipeline by Molecular Targeting Technologies Inc, H2 2020

Rabies - Pipeline by NanoViricides Inc, H2 2020

Rabies - Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, H2 2020

Rabies - Pipeline by Oita University Institute of Advanced Medicine Inc, H2 2020

Rabies - Pipeline by Sanofi, H2 2020

Rabies - Pipeline by Shandong Yidu Biotechnology Co Ltd, H2 2020

Rabies - Pipeline by Shanghai Qingsai Biotechnology Co Ltd, H2 2020

Rabies - Pipeline by Synermore Biologics Co Ltd, H2 2020

Rabies - Pipeline by Trellis Bioscience Inc, H2 2020

Rabies - Pipeline by Univercells SA, H2 2020

Rabies - Pipeline by Yisheng Biopharma Co Ltd, H2 2020

Rabies - Dormant Projects, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Rabies, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Targets, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

## I would like to order

Product name: Rabies - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/R67EB50D79DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R67EB50D79DEN.html>